Parasitological and immunological follow-up of American tegumentary leishmaniasis patients.
A long-term evaluation of human American tegumentary leishmaniasis patients was conducted to detect immunological and/or parasitological indicators associated with cure or protection against leishmaniasis. Cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML) patients from endemic areas of Leishmania braziliensis infection in Brazil were studied during the active disease, at the end of therapy, and up to 10 years after the end of therapy. For immunological studies, lymphocyte proliferative responses, phenotypic characterization of CD4+ and CD8+ T cells reactive to L. braziliensis and cytokine production in vitro were assayed. In CL, with its tendency for healing lesions, at or shortly after the completion of therapy the ratio of CD4+ to CD8+ T cells was approximately one and production of interferon gamma (IFN gamma) remained roughly constant. In ML, these apparently beneficial CD4+/CD8+ ratios and cytokine patterns appeared later. The long-term memory T cell responses were associated with preferential induction of CD4+ subpopulations and IFN gamma production that probably led to protection against relapses or reinfection. Deoxyribonucleic acid (DNA) was isolated from peripheral blood and oligonucleotides that amplify the conserved region of the minicircle molecules of Leishmania were used in a 'hot-start' polymerase chain reaction (PCR). Leishmania DNA was found in about one-quarter of the patients with active disease as well as in individuals who had received chemotherapy. The PCR was also positive in one-third of the individuals with a positive skin test but no past or present history of leishmaniasis. The well-modulated T cell response leading to long-term protection observed in CL patients could result from a favourable host genetic background and/or a particular parasite genotype, leading to a beneficial T cell immune response even in the presence of parasite antigens. The possibility of parasite persistence after clinical cure suggests that the immune response can control, but not fully eliminate, the infection. It could prevent the parasite from causing disease, maintaining a leishmanial antigen-specific response and hampering reinfection.
Coutinho
Sergio G
SG
Laboratório de Imunidade Celular e Humoral em Protozooses, Departamento de Imunologia, Fundaçao Oswaldo Cruz, Rio de Janeiro, RJ, Brazil. scoutin@ioc.fiocruz.br
Pirmez
Claude
C
Da-Cruz
Alda Maria
AM
D000818:Animals; D016054:DNA, Protozoan / Q000032:analysis; D005500:Follow-Up Studies; D006801:Humans; D007111:Immunity, Cellular; D007892:Leishmania braziliensis / Q000276:immunology / Q000302:isolation & purification*; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy / Q000276:immunology / Q000469:parasitology*; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy / Q000276:immunology / Q000469:parasitology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D016896:Treatment Outcome
D016054:DNA, Protozoan